Medidata, ClinChoice Extend Partnership To Enhance Clinical Trial Efficiency, Innovation

KUALA LUMPUR, Dec 20 (Bernama) -- Medidata, a Dassault Systèmes brand and provider of clinical trial solutions to the life sciences industry, has renewed its long-standing enterprise partnership with ClinChoice, a global contract research organisation (CRO).

Under this new agreement, ClinChoice will utilise the Medidata Platform to streamline study data and supply management, boost trial efficiency, and accelerate growth as a full-service CRO in Asia, Europe, and North America.

ClinChoice also plans to prioritise Clinical Data Studio accreditation, further enhancing its capabilities through a transformative artificial intelligence (AI)-powered data quality management experience.

Medidata senior vice president and general manager, APAC, Edwin Ng in a statement said ClinChoice’s dedication to innovation and patient-centred approaches makes them an invaluable partner.

“With this renewed partnership, we look forward to empowering ClinChoice with Medidata’s advanced solutions to further streamline their trial operations, expand their global reach, and accelerate access to life-changing therapies for patients worldwide,” he said.

Meanwhile, ClinChoice global chairman and chief executive officer, Ling Zhen noted that since the company’s first implementation of Medidata Rave EDC in 2011, its partnership with Medidata has supported its development, starting in the United States, then China, and eventually to the wider global stage.

“We are delighted to extend our work together to include Medidata’s Clinical Data Studio and other advanced technologies to further boost our expansion,” Ling added.

ClinChoice’s commitment in utilising Medidata’s solution has spanned over a decade, facilitating secure connections among patients, sites, and sponsors within a unified cloud environment.

By integrating Medidata’s solutions, ClinChoice continues to strengthen its operational efficiency and position itself for growth in today’s increasingly complex clinical trial landscape.

-- BERNAMA